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Abstract
We use fMRI to examine brain activity for pain elicited by palpating joints in a single patient suffering
from psoriatic arthritis. Changes in these responses are documented when the patient ingested a
single dose of a selective cyclooxygenase-2 inhibitor (COX-2i). We show that mechanical
stimulation of the painful joints exhibited a cortical activity pattern similar to that reported for
acute pain, with activity primarily localized to the thalamus, insular, primary and secondary
somatosensory cortices and the mid anterior cingulum. COX-2i resulted in significant decreased in
reported pain intensity and in brain activity after 1 hour of administration. The anterior insula and
SII correlated with pain intensity, however no central activation site for the drug was detected. We
demonstrate the similarity of the activation pattern for palpating painful joints to brain activity in
normal subjects in response to thermal painful stimuli, by performing a spatial conjunction analysis
between these maps, where overlap is observed in the insula, thalamus, secondary somatosensory
cortex, and anterior cingulate. The results demonstrate that one can study effects of
pharmacological manipulations in a single subject where the brain activity for a clinical condition is
delineated and its modulation by COX-2i demonstrated. This approach may have diagnostic and
prognostic utility.
Introduction
Over the last fifteen years, functional MRI (fMRI) and pos-
itron emission tomography (PET) have been used to
unravel brain circuitry underlying pain perception and
study the properties of these areas in acute and chronic
pain conditions (for a recent review see [1]). Recently, the
utility of combining fMRI with pharmacology has been
demonstrated by a number of groups [2-6]. Brain imaging
studies in combination with various analgesics have also
been described regarding the impact of examined chemi-
cals on brain activity for pain [7-11]. These studies exam-
ine acute experimental pain conditions, and demonstrate
the possibility of delineating brain regions modulated in
normal subjects, for centrally acting drugs, such as opiates
and ketamine. In the present study we show the potential
of studying clinical pain conditions, and tracking the effi-
cacy of pharmacological interventions in an individual
patient, where multiple repeat scans are performed before
and after administering a single dose of the analgesic that
the patient was using to manage satisfactorily his arthritis.
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A. Example pain intensity rating for manually palpating painful arthritic joints (grey areas is duration of palpation) Figure 1
A. Example pain intensity rating for manually palpating painful arthritic joints (grey areas is duration of palpation). Right panel 
shows that the mean rating of pain intensity for palpating painful joints, which significantly decreased 1 and 3 hours after admin-
istration of COX-2i when compared to the baseline (p < 0.001). B. Brain activity in ten consecutive scans is presented for pal-
pating painful joints (each column is a separate scan). The first 4 scans are prior to drug ingestion (pre COX-2i), the next four 
start 1 hour post drug ingestion, the last two are 3 hours post-drug ingestion. Four transverse slices are shown for each scan 
(top to bottom: z = -12, 10, 28 and 44). Note that brain activity decrease after cox-2i is evident in these individual scans. C. 
Average group activity minus visual controls using fixed effects analysis for palpating painful joints across all conditions (pre and 
post COX-2i). Activity is seen bilaterally in insular cortex and thalamus, in addition to right primary and secondary somatosen-
sory areas and mid anterior cingulum. Activity maps are presented in MNI space, x y z coordinates in mm.Molecular Pain 2005, 1:32 http://www.molecularpain.com/content/1/1/32
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We examine the analgesic efficacy of a selective cyclooxy-
genase-2 (COX-2) inhibitor on psoriatic arthritis pain.
Traditional nonsteroidal anti-inflammatory drugs
(NSAIDs) are nonselective inhibitors of COX-1 and COX-
2, which catalyze transformation of arachadonic acid to
prostaglandin. Substantial clinical evidence shows that
COX-2 selective inhibitors are effective for treating oste-
oarthritis, rheumatoid arthritis, and other inflammatory
pain conditions [12]. Differential elevation of COX-2 has
been documented in synovial tissue of patients with
inflammatory arthritis, including patients with psoriatic
arthritis [13], and in animal studies of inflammatory pain
COX-2 elevation is observed in the periphery and in the
central nervous system [14]. Thus, there is good scientific
evidence for management of inflammation and pain of
psoriatic arthritis with selective COX-2 inhibitors (COX-
2i). Here we examine the effects of a single dose of a COX-
2i on brain activity for joint pressure allodynia associated
with psoriatic pain.
Results
A single subject with psoriatic pain was studied. The sub-
ject skipped a single dose of his COX-2i 12 hours prior to
the scanning session. Brain activity was performed for pal-
pating the painful joints in 4 fMRI scans prior to adminis-
tration of COX-2i, in 4 fMRI scans 1 hour post drug
ingestion, and in 2 fMRI scans 3 hours post drug inges-
tion.
COX-2i treatment decreased pain
A single 200 mg dose of selective COX-2i reduced baseline
pain, joint stimulation pain, and restored ability to ambu-
late. At the start of the study the patient was not able to
stand on his legs due to severe ankle joint pain. One hour
after ingesting the medicine he still had very limited
mobility. After three hours, he was able to walk. Left panel
of Figure 1A shows an example rating of pain when joints
of the hand are palpated (collected during an fMRI ses-
sion, prior to ingesting the COX-2i), where the average
baseline pain is about 3 and stimulus-evoked pain is
about 6 (on a 0–10 pain scale, 10 = maximum imaginable
pain). The medication decreased baseline pain by 50%
(over 4 hours post-treatment); stimulus evoked pain from
7.93 +/- 0.73 to 3.15 +/- 0.55 (1 hour post COX-2i, p <
0.001), to 2.2 +/- 0.12 (3 hours post COX-2i, p < 0.001
(right panel of figure 1A).
COX-2i treatment decreased pain related brain activity
We observe widespread brain activity for palpating pain-
ful joints prior to drug administration. This activity was
significantly attenuated across all areas 1 hour after inges-
tion of COX-2i, and there was no significant brain activity
after 3 hours of drug ingestion (figure 1B).
Overall brain activity for palpating painful joints was
determined by averaging all 10 scans, prior and post-drug
ingestion. The activity mainly included areas coding the
sensory properties of the acute painful stimulus, including
bilateral anterior and posterior insula together with sec-
ondary somatosensory cortex, multiple portions of ante-
rior cingulate, primary somatosensory cortex, basal
ganglia, and thalamus (Figure 1C, Table I).
Brain areas that correlated with pain intensity ratings are
shown in figure 2. The main areas include anterior insular
cortex, and secondary sensory/posterior insular cortex.
Table 1: Brain regions activated for palpating painful joints in a psoriatic arthritis patient
Region Coordinates Z value Cluster Index Voxels P value
xy z
R sup temporal pole 46 6 -6 6.24 10 835 p < 10-14
R ant insula * 40 20 -6 3.98 10
R inf parietal, S2 * 42 -22 16 3.93 10
L ant insula * -42 22 -2 4.66 9 321 p < 10-06
L ant insula/inf frontal (45/47) -48 20 -6 4.52 9
R ant thalamus 10 -4 6 3.65 8 258 p < 10-05
R putamen 26 6 -4 2.70 8
R S1 hand (3) * 44 -20 48 5.43 7 210 p < 10-04
R S1/M1 hand (3/4) 38 -28 68 4.08 7
R mid temporal 68 -22 8 4.56 6 203 0.000117
bi lingual -4 -66 10 4.57 5 200 0.000136
R thalamus * 16 -22 8 4.56 4 187 0.000263
mid ACC (24) * 2 22 34 4.48 3 158 0.00122
R SMA (6) 10 -6 52 3.68 2 135 0.00439
L thalamus * -12 -24 6 4.01 1 123 0.0088
L = left; R = right; bi = bilateral; mid = middle; ant = anterior; inf = inferior; post = posterior; sup = superior ; S1 = primary somatosensory cortex; 
S2 = secondary somatosensory cortex; M1 = primary motor cortex; ACC = anterior cingulate; SMA = supplementary motor area; numbers in 
parenthesis = Brodmann areas. Activity for brain areas marked by * are shown in Figure 1C.Molecular Pain 2005, 1:32 http://www.molecularpain.com/content/1/1/32
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The average BOLD signal in these two areas shows the
response profile of brain activity in each region and the
decrease in magnitude of this response after drug inges-
tion. In both regions, magnitude of activity (Z-values) is
strongly correlated with pain ratings (figure 2 last two
panels).
It is worthy to note that no brain areas showed significant
increases in activity after the administration of drug (i.e.
the contrast: post – pre drug ingestion scans yielded no
positive results, and no brain areas were negatively corre-
lated with pain). Thus, we could not identify any brain
area responding to the drug.
Overlap between brain activity in the patient with 
psoriatic pain and acute thermal pain in normal subjects
The average brain activity pattern for palpating joints in
the psoriatic arthritis patient closely resembles brain activ-
ity observed for acute pain, as reported by many groups in
the past, see recent review [1]. To directly demonstrate this
similarity we compared the spatial activity pattern in this
patient to group-averaged brain activity in normal sub-
jects following thermal painful stimulation. This similar-
ity is illustrated in figure 3. The overlap between these
activation maps included bilateral thalamus and insula,
anterior cingulate, and secondary somatosensory cortex.
Discussion
The study demonstrates feasibility of studying effects of a
single dose of an analgesic on brain activity for a clinical
pain condition in an individual subject. We show that
even in a single subject using repeated fMRI scans it is pos-
sible to demonstrate the efficacy of an analgesic in rela-
tion to brain activity, to identify the regions involved in
the pain, and the regions specifically modulated by the
analgesic.
Peripheral vs. central actions of COX-2 inhibitors remains
unknown in man, although there is evidence for their cen-
tral efficacy in rodents [14]. We could not identify brain
regions responding to the drug, independent of pain
modulation, implying that the drug-induced analgesia is
probably not mediated through active inhibition at the
level of the cortex. However, this negative finding may
also be due to many other reasons (like insufficient
power), especially since this is a single subject study, and
needs to be determined in a larger population of patients.
The pattern of brain activity observed for the psoriatic
arthritis joint pain is similar to brain activity observed by
many groups for acute pain, and especially for acute ther-
mal painful stimuli, see for example [15-18], and many
others [1]. A recent meta-analysis of human brain imaging
studies regarding regional activity for acute pain indicates
that incidence of activity for anterior cingulate, primary
somatosensory, secondary somatosensory, and insular
cortices, as well as the thalamus ranges from 75% to 94%
[1]. Consistent with these observations recent rodent
studies indicate that manipulating activity in anterior cin-
gulate and insula can modify pain-like behavior [19-21].
All of these regions were identified as activated in our pso-
riatic arthritis patient, and most of them (all but primary
somatosensory cortex) showed overlap of activity
between psoriatic pain and thermal pain in normal sub-
jects. Anterior insula and secondary somatosensory cor-
tex/posterior insula were the two brain regions that
robustly reflected changes in pain perception as a conse-
quence of ingesting the COX-2i. A number of groups have
studied brain regions specifically coding painful stimuli
for acute pain [16,22,23]. The study by Bornhovd et al.
[22] examined laser stimulation evoked responses and
differentiated between detection of painful stimuli vs.
coding of painful stimuli, and showed that anterior insula
and secondary somatosensory cortex are the ones that best
code pain intensity. Thus, the psoriatic pain modulation
by COX-2i closely agrees with the results of Bornhovd et
al. [22]. In contrast, our recent study of brain activity in
chronic back pain patients with radiculopathy, and using
a data collection and analysis approach identical to the
present study, indicated that back pain intensity was rep-
resented in medial prefrontal cortex activity, while dura-
tion of back pain was reflected by anterior insula activity
(preliminary report by Baliki et al. Society Neuroscience
Abstract 2003). Therefore, at least in the subject that we
have studied, the psoriatic arthritis joint pain seems more
like acute thermal pain and less like chronic neuropathic
back pain. This result is consistent with the clinical assess-
ment of psoriatic arthritis being more an inflammatory
condition than neuropathic [13] and the patient's respon-
siveness to the COX-2i is in agreement with animal stud-
ies showing that COX-2 expression and responsiveness to
COX-2i seems specific to inflammatory rather than neuro-
pathic pain conditions [14,24], but of course this notion
remains to be demonstrated in a population of psoriatic
arthritis patients.
In conclusion, this case study has important clinical
implications in making judgments as to the efficacy of
pharmacotherapies on brain circuitry for clinical pain
conditions that a patient may be suffering from, and dem-
onstrates a method that can identify brain regions that
may differentiate between patients with similar clinical
conditions but with different responses to the same phar-
macotherapy. In general, the methodology provides an
objective approach that may be used for drug develop-
ment and testing effects of drugs in individual cases.
Materials and methods
A single patient with psoriatic arthritis pain in multiple
joints was recruited to the study. An additional 7 healthyMolecular Pain 2005, 1:32 http://www.molecularpain.com/content/1/1/32
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subjects were studied for thermal pain. Subjects were
instructed regarding the procedure and signed a consent
form. Institutional Review Board of Northwestern Univer-
sity approved the procedures.
The patient agreed to skip one dose of the analgesic and
anti-inflammatory selective COX-2i (200 mg Celebrex
every 12 hours, Pfizer) 12 hours prior to the start of the
study. The subject knew that this would dramatically limit
his mobility and requested help in transportation from
home to the scanner. The subject rated his pain on a ver-
bal analog scale (0 = no pain, 10 = most imaginable pain)
at the start of the study and at different time intervals
throughout the course of the study. The participant's abil-
ity to ambulate was tested at the start and at various inter-
vals during the study, as an alternate measure for knee
joint pain. He underwent 10 joint palpation scans, 4 prior
and 6 after ingesting the analgesic, 2 fMRI scans for visual-
motor controls, and anatomic scans for proper registra-
tion of the fMRI scans to standard space.
Brief outline of case history
The subject was a 53 year old male with a past medical his-
tory significant for plantar-palmar psoriasis and mild gas-
tric reflux from a small hiatal hernia. Past medical history
was notable only for a lack of any orthopedic procedures
on any joints. The psoriasis had been present since age 39,
but 7 months prior to his participation in this investiga-
tion, the psoriasis became acutely more severe but
remained purely a dermatologic problem. At 3 months
prior to the investigation, the patient noted an acute onset
of swelling in the left knee associated with significant pain
on movement. This was clinically diagnosed as psoriatic
arthritis, and within weeks involved all joints of the
extremities with severe swelling and pain with movement.
Further, pain along the entire spine was noted. The sever-
ity of the pain significantly interfered with sleep and with
all activities of daily living. Daily doses of ibuprofen of 3.2
g and of naprosyn 2.4 g failed to control the pain. After 3
months of poorly controlled pain, he was started on
celecoxib 200 mg bid. Within 1 hour of the first dose, pro-
Higher-level covariate analysis between pain intensity for palpating joints (mean rating of pain during scan) and brain activity  across all 10 scans results in two main clusters: left insular cortex (red) R2 = 0.78 and right secondary somatosensory area  (blue) R2 = 0.77 Figure 2
Higher-level covariate analysis between pain intensity for palpating joints (mean rating of pain during scan) and brain activity 
across all 10 scans results in two main clusters: left insular cortex (red) R2 = 0.78 and right secondary somatosensory area 
(blue) R2 = 0.77. Middle panels show the average change in BOLD signal during stimulation (mean stimulus duration = 13.3 sec-
onds) for these areas prior to, and 1 and 3 hours after the administration of COX-2i. Right panels show the relationship 
between activity (Z score) and pain for a 1 cc volume centered at the peak of the covariate analysis, for each region.Molecular Pain 2005, 1:32 http://www.molecularpain.com/content/1/1/32
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found relief was noted, and this relief was sustained
throughout the use of the medication allowing him to
sleep and restore full activities of daily living. However,
despite the pain control with the celecoxib, joint swelling
was unchanged.
Brain Imaging
Brain activity was studied with fMRI while the patient
rated fluctuations of ongoing pain using a finger-spanning
device to continuously rate and log subjective perception
of pain during fMRI data collection [25]. The patient
underwent an initial training phase prior to scanning, in
which he learned to use the finger-span device. During
brain imaging sessions, the finger span device is synchro-
nized and time locked with fMRI image acquisition and
connected to a computer providing visual feedback. This
device was also used in performing visual control scans.
Rating pain during stimulation of arthritic joints
The patient rated the stimulus pain with the finger-span
device. During a given functional imaging session, 10
stimuli ranging in duration from 10 to 15 seconds were
applied to the arthritic limbs and digits. (see fig 1A). The
patient rated pain on a scale of 0 to 10 and was provided
with a visual feedback of the rating. The stimulus was
delivered manually by an investigator who applied varia-
ble duration and intensity pressures on the painful joints.
Stimulus intensity was non-painful when applied on the
investigator but was always rated painful (of variable
intensity) by the patient. In some scans stimuli were
applied to the hand joints (left and right), in others to the
kneecap (left and right). Given the small number of fMRI
scans, we did not attempt to distinguish between stimulus
sites (neither body side nor upper vs. lower limb distinc-
tions were tested).
Rating pain during thermal stimulation in healthy normals
Healthy volunteers (n = 7; average age = 30.3 ± 3.2) were
scanned during acute thermal stimulation where they
rated the stimulus pain with the finger-span device. Dur-
ing a given functional imaging session, 9 noxious thermal
stimuli ranging in duration from 10 to 30 seconds were
applied to the healthy subjects. The stimuli were applied
both on the lower back area and volar surface of the
hands. Subjects were instructed to rate their pain on a
scale of 0 to 10 and were provided with a visual feedback
of their rating (average reported pain across all subjects
and runs was 5.0 ± 1.6). A purpose built, fMRI compatible
thermal stimulator delivered fast ramping (10°C per sec-
ond) painful thermal stimuli (baseline 38°C, peak tem-
peratures 46°C and 48°C) via a contact probe (1 × 1.5 cm
peltier). Durations and intensities of thermal stimuli as
well as inter-stimulus intervals were presented in a pseu-
dorandom fashion. This variation in interval was adopted
to decrease the regularity of stimulus presentation and
thus reduce volunteers' ability to predict the arrival of the
next stimulus. In addition, the relatively long duration
inter-stimulus interval reduced sensitization.
Visual control
The patient and normal subjects were instructed to follow
as closely as possible fluctuations of a bar projected on a
screen in time. This visual tracking provides an adequate
visual-motor control since it is similar to the pain rating
finger-span task, with the important difference being that
now the finger movement (i.e. variations in magnitude) is
correlated with a visual input rather than pain.
Functional Magnetic Resonance Data Analysis
Functional MR data for the arthritic patient was acquired
with a 1.5T Siemens (VISION) whole-body scanner with
echo-planar imaging (EPI) capability using the standard
radio-frequency head coil. Multi-slice T2*-weighted echo-
planar images were obtained with the following parame-
ters: repetition time TR = 3.5 s, echo time TE = 70 ms, flip
angle = 90°, slice thickness = 3 mm, in-plane resolution =
3.475 × 3.475 mm2. The 36 slices covered the whole brain
from the cerebellum through to the vertex. An average of
240 volumes were acquired per event per condition in all
participants. A No-Flow T1-weighted anatomical MRI
image was also using the following parameters: TR = 22
Similarity of brain activity for psoriatic pain in a single subject  to thermal pain in a group of normal subjects Figure 3
Similarity of brain activity for psoriatic pain in a single subject 
to thermal pain in a group of normal subjects. Top panel: The 
close proximity of brain activity is shown for the entire brain. 
Average group activity maps for thermal painful stimuli in 7 
healthy control subjects (red) and for palpating painful joints 
in one patient (blue). Conjunction analysis between heat pain 
in healthy normal subjects and psoriatic arthritis pain indi-
cates regions of overlap (outlined in black in lower panels), 
including: bilateral insula (z = -8 to +4) and thalamus (z = +4), 
ACC (z = 34), and right S2 region (z = +10 to +22\).Molecular Pain 2005, 1:32 http://www.molecularpain.com/content/1/1/32
Page 7 of 8
(page number not for citation purposes)
ms, TE = 5.6 ms, flip angle = 20°, matrix 256 × 256 and a
FOV of 240 mm, with 160 mm coverage in the slice direc-
tion. Anatomic images were used to register functional
images in standard space.
Functional MR data for thermal pain in normal healthy
subjects were acquired with a 3T Siemens Trio whole-
body scanner with echo-planar imaging (EPI) capability
using the standard radio-frequency head coil. Multi-slice
T2*-weighted echo-planar images were obtained with the
following parameters: repetition time TR = 2.5 s, echo
time TE = 70 ms, flip angle = 90°, slice thickness = 3 mm,
in-plane resolution = 3.475 × 3.475 mm2. The 36 slices
covered the whole brain from the cerebellum to the ver-
tex. An average of 400 volumes were acquired per event
per condition in all participants. A T1-weighted anatomi-
cal MRI image was also acquired for each subject using the
following parameters: TR = 2.1 s, TE = 4.38 ms, flip angle
= 8°, FOV = 220 mm, slice thickness = 1 mm, in-plane res-
olution = 0.86 × 0.86 mm2 and number of sagittal slices =
160.
Image analysis to reveal significant brain activity based on
changes in BOLD signal was performed using FMRIB
Expert Analysis Tool (FEAT, [26], http://
www.fmrib.ox.ac.uk/fsl). The preprocessing of each sub-
ject's individual scan time-series of fMRI volumes encom-
passed: slice time correction; motion correction using
MCFLIRT; spatial smoothing using a Gaussian kernel of
full-width-half-maximum 5 mm; nonlinear high-pass
temporal filtering (Gaussian-weighted least-squares
straight line fitting, filter cutoff of 100 seconds) and sub-
traction of the mean of each voxel time-course from that
time-course (i.e. intensity normalization). The fMRI sig-
nal was then linearly modeled on a voxel by voxel basis
using FMRIB's Improved Linear Model (FILM) with local
autocorrelation correction [27,28].
Each condition described above (thermal pain, arthritic
pain and visual ratings) was considered to generate a
hemodynamic response described by the convolution of
the corresponding finger span rating with a generalized
hemodynamic response function (gamma function: lag =
6 seconds, standard deviation = 3 seconds). Head motion
vector (derived from motion correction) was used at this
level as a covariate of no interest to further remove any
residual variance due to head motion. The significance of
the model fit to each voxel time-series was calculated,
yielding statistical parametric maps for each scan. Average
group activity maps were generated by subtracting the vis-
ual control scans from the pain activity maps using FEAT
in a second level random and fixed effects group analysis,
following the co-registration of individual scans to stand-
ard space (152 subject average Montreal Neurological
Institute (MNI) space, http://www.bic.mni.mcgill.ca/cgi/
icbm_view). This results in a Z-score map of statistically
significant pain-related activity across different condi-
tions. For random-effects, cluster-based correction of the
Z-statistic images was performed. The raw Z-statistic
images from the group analysis were thresholded at Z-
scores > 2.3. For each resulting cluster of spatially con-
nected voxels surviving the Z threshold, a cluster probabil-
ity threshold of P = 0.01 was applied to the computed
significance of that cluster, which corrects for multiple
comparisons [29].
Stereotactic coordinates of local maxima within areas of
significant activity change were determined for each con-
dition. The localization of these local maxima and clusters
was determined and assessed by reference to a standard
stereotactic atlas [30] and reported in MNI coordinates.
Covariate analysis for arthritic pain was performed for all
stimulation scans with mean pain rating of each scan. This
is a higher level analysis where first level brain activity
maps are used to determine brain regions that correlate
across all scans with the corresponding pain intensity. The
resultant map shows clusters of voxels that significantly
covary with pain intensity across scans. Based on the
results of this analysis, we perform a regional correlation
analysis using the mean Z-value of a 27-voxel (1 cc) vol-
ume centered at the peak within a cluster of interest, relat-
ing this value to pain intensity across scans.
Central activation by COX 2i was investigated by a higher
level analyses that was performed to determine brain
areas that shows increased activity post COX-2i. A simple
linear model was utilized in the set up of this covariate
analyses: scans performed 3 hours post, 1 hour post and
pre COX-2i were regressed with 1,0,-1 respectively. No
brain areas exhibited significant corrolation (i.e. no voxels
had a linear increase in activity across the 3 sessions).
Average time-course of BOLD response for arthritic pain
was calculated for each fMRI scan by and then averaged
across session. Pre-processed fMRI images are re-averaged
relative to the start time of stimuli, 2 brain volumes (7 sec-
onds) prior to the start time and 9 (31.5 seconds) post-
start time. The average duration of stimuli across all scans
is 13.3 seconds. Time-courses for coordinates of interest
are then extracted from each scan, averaged over the 27-
voxel neighborhood, and then averaged across sessions.
Variability of these curves is expressed in S.E.M. over the
scans. These BOLD responses show the time-course of
activity in a given brain region relative to the stimulus,
and indicate its changes at different time points from drug
ingestion.
The thermal pain responses in normal subjects was used
to indicate the spatial similarity between this map and thePublish with BioMed Central    and   every 
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map obtained for psoriatic pain. Overlap between the two
maps was identified using conjunction analysis, where a
spatial mask is generated from the group-averaged ther-
mal map, thresholded as Z-value > 2.3. The intersection
between this mask and brain activity for psoriatic pain
(averaged across all scans) determines brain regions com-
monly activated in both conditions. It is important to
note that no statistical comparisons were made for inten-
sity of activity between maps for thermal stimulation in
normal healthy volunteers and arthritic pain since each
data were collected on different strength magnets.
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